Intestinal Inflammation Targets Cancer-Inducing Activity of the Microbiota

See allHide authors and affiliations

Science  05 Oct 2012:
Vol. 338, Issue 6103, pp. 120-123
DOI: 10.1126/science.1224820

Of Microbes and Cancer

Inflammation is a well-established driver of tumorigenesis. For example, patients with inflammatory bowel disease have an elevated risk of developing colorectal cancer (CRC). Whether the gut microbiota also contributes to the development of CRC is less well understood. Arthur et al. (p. 120, published online 16 August; see the Perspective by Schwabe and Wang) now show that the microbiota does indeed promote tumorigenesis in an inflammation-driven model of CRC in mice. Although germ-free mice were protected against developing cancer, colonization of mice with Escherichia coli was sufficient to drive tumorigenesis.


Inflammation alters host physiology to promote cancer, as seen in colitis-associated colorectal cancer (CRC). Here, we identify the intestinal microbiota as a target of inflammation that affects the progression of CRC. High-throughput sequencing revealed that inflammation modifies gut microbial composition in colitis-susceptible interleukin-10–deficient (Il10−/−) mice. Monocolonization with the commensal Escherichia coli NC101 promoted invasive carcinoma in azoxymethane (AOM)–treated Il10−/− mice. Deletion of the polyketide synthase (pks) genotoxic island from E. coli NC101 decreased tumor multiplicity and invasion in AOM/Il10−/− mice, without altering intestinal inflammation. Mucosa-associated pks+ E. coli were found in a significantly high percentage of inflammatory bowel disease and CRC patients. This suggests that in mice, colitis can promote tumorigenesis by altering microbial composition and inducing the expansion of microorganisms with genotoxic capabilities.

Chronic inflammation is a well-established risk factor for several cancers, including colorectal cancer (CRC) (1). Although the mechanism by which chronic intestinal inflammation leads to CRC is still unclear, numerous experimental studies suggest that inflammatory cells and their associated mediators such as interleukin-6 (IL-6), tumor necrosis factor–α (TNF-α), IL-23, and reactive oxygen species form a microenvironment favoring the development of CRC, presumably by enhancing DNA damage in epithelial cells (24).

In the colon, trillions of commensal bacteria, termed “the microbiota,” are in close proximity to a single layer of epithelial cells. A critical question is whether these microorganisms actively participate in the process of carcinogenesis. We have previously shown that microbial status modulates development of colitis-associated CRC by using the colitis-susceptible Il10−/− mouse strain (5). To evaluate the effect of inflammation and carcinogenesis on the colonic microbiota, we used Illumina (San Diego, California) HiSeq. 2000 sequencing targeting the hypervariable V6 region of the 16S ribosomal RNA (rRNA) gene in mucosal biopsies and stool samples of Il10−/− and wild-type (WT) mice, in the presence and absence of the colon-specific carcinogen azoxymethane (AOM). Germ-free (GF) Il10−/− and control WT adult mice were transferred to specific pathogen–free (SPF) conditions for 20 weeks. During this time frame, 100% of Il10−/− mice develop colitis; with the addition of AOM, 60 to 80% of mice develop colon tumors (5). WT mice developed neither colitis nor tumors (5). We first compared the luminal microbiota between all Il10−/− (colitis/cancer) and WT mice (healthy control) and found that the microbiota of Il10−/− mice clustered apart from those of WT controls [analysis of similarity (ANOSIM) R = 0.925, P = 0.002] (Fig. 1A and fig. S1). The altered microbiota of Il10−/− mice showed reduced richness as compared with that of WT controls (P < 0.0001) (Fig. 1B). Analysis of mucosal biopsies revealed the colonic-adherent microbiota of AOM/l10−/− mice with colitis/cancer clustered apart from healthy AOM/WT controls (fig. S2A), with alterations in microbial evenness but not richness (P = 0.023) (fig. S2B). To determine the impact of AOM on the microbiota in the context of inflammation, we compared the luminal microbiota of Il10−/− mice with colitis with that of AOM/Il10−/− mice with colitis/cancer and found that AOM treatment had no significant effect on luminal microbial composition or richness in Il10−/− mice (Fig. 1, C and D). These data suggest that inflammation rather than cancer is associated with the observed microbial shifts.

Fig. 1

Inflammation alters fecal microbial community structure. (A and B) Luminal microbiota of Il10−/− versus WT mice. (A) Operational taxonomic unit (OTU) abundances were standardized by total, square root transformed, and assembled into a Bray Curtis similarity matrix to generate a multidimensional scaling (MDS) plot, where in these plots each symbol represents the microbiota of an individual mouse analyzed by means of Illumina sequencing of 16S V6 region. Il10−/− versus WT comparison is by ANOSIM, R = 1 is maximum dissimilarity. (B) Richness, mean + SEM of cage means, five to six cages per group, two to four mice per cage, t test. (C and D) Luminal microbiota of AOM/Il10−/− versus Il10−/− (C) MDS plot, AOM/Il10−/− versus Il10−/−comparison by ANOSIM. (D) Richness, mean + SEM of cage means, two to three cages per group, two to four mice per cage, t test. (E to G) Standardized transformed abundance, median + SEM of cage means, five to six cages per group, two to four mice per cage, Mann Whitney U test. (H) MDS plot depicting luminal microbiota of Il10−/− versus WT, overlaid with Enterobacteriaceae abundance depicted by circle size. (I) E. coli ΔCt relative to total bacteria (16S). Each symbol depicts one mouse, line at median, Mann Whitney U test.

We then hypothesized that inflammation-induced changes in microbial composition include the expansion of bacteria within the Proteobacteria phylum because several members have been associated with colitis and CRC (69). Analysis of phylum-level distribution revealed that inflammation in Il10−/− mice was associated with significantly increased levels of luminal Verrucomicrobia, Bacteroidetes, and Proteobacteria as compared with that of WT controls (fig. S3). Although Verrucomicrobia significantly differed between groups, this phylum is not well characterized, restricting detailed molecular analysis. Within Proteobacteria, however, the Gammaproteobacteria class, Enterobacteriales order, and Enterobacteriaceae family were all significantly more abundant in Il10−/− mice (Fig. 1, E to H). Because E. coli are members of the family Enterobacteriaceae and adherent-invasive E. coli have been associated with human inflammatory bowel disease (IBD) and CRC (8, 1013), we determined by means of quantitative polymerase chain reaction (PCR) whether E. coli was more abundant in the context of inflammation in Il10−/− mice. We found that relative to WT mice, the luminal microbiota of Il10−/− mice exhibited a ~100-fold increase in E. coli (Fig. 1I). AOM treatment did not affect E. coli abundance (fig. S4A). Total bacterial loads between WT and Il10−/− mice did not differ (fig. S4B), nor did levels of the common commensal Lactobacillus (fig. S4C).

To determine the causative effect of commensal E. coli on CRC, we administered AOM to GF Il10−/− mice mono-associated with either the commensal mouse adherent-invasive E. coli NC101 or the human commensal Enterococcus faecalis OG1RF, both of which cause aggressive colitis in Il10−/− mice (14). As expected, both E. coli NC101 and E. faecalis mono-associated, AOM-treated Il10−/− mice developed severe colitis (Fig. 2A). Despite similar levels of colitis, 80% of E. coli mono-associated mice developed invasive mucinous adenocarcinoma, whereas E. faecalis mono-associated mice rarely developed tumors (Fig. 2, B to D). Colonic cytokines involved in inflammation and carcinogenesis including Il6, Tnfa, Ifng, Il1b, Il18, Il17, and Il23 were not significantly different between AOM-treated E. coli and E. faecalis mono-associated mice (Fig. 2E, fig. S5, and tables S1 and S2). In addition, infiltrating CD3+ T cells, F4/80+ macrophages, and Ly6B.2+ monocytes and neutrophils were similar between AOM-treated E. coli and E. faecalis mono-associated mice (fig. S6). These observations demonstrate that in addition to inflammation, bacteria-specific factors may be required for the development of colitis-associated CRC.

Fig. 2

Colonization of germ-free mice Il10−/− mice with E. coli (E.c.) or E. faecalis (E.f.) differentially affects tumorigenesis without affecting inflammation. (A) Histologic inflammation scores, t test. (B) Macroscopic tumor counts; two-tailed Mann Whitney U rank sum test. (C) Percent of mice with invasive adenocarcinoma; Fisher’s exact test. (D) Representative hematoxylin and eosin (H&E) histology. In (A) to (D), mean + SEM, 7 to 12 per group, single experiment. (E) Colonic cytokine mRNA expression relative to GF Il10−/−; mean + SEM, four samples per group, t test.

We hypothesized that E. coli NC101 has carcinogenic capabilities not shared by E. faecalis. Several members of the family Enterobacteriaceae, including select E. coli strains of B2 phylotype, harbor a ~54-kb polyketide synthases (pks) pathogenicity island that encodes multi-enzymatic machinery for synthesizing a peptide-polyketide hybrid genotoxin named Colibactin (1518). A bioinformatics Basic Local Alignment Search Tool (BLAST) search of the E. coli NC101 genome (accession NZ_AEFA00000000) revealed the presence of pks and the absence of other known E. coli genotoxins Cif, CNF, and CDT. Using PCR and sequencing (15), we detected the pks island in E. coli NC101 but not in E. faecalis or non-colitogenic E. coli K12 (Fig. 3A). To determine whether E. coli pks is associated with human CRC or IBD, we screened mucosa-associated E. coli strains isolated from colorectal tissue specimens of 35 patients with IBD, 21 with CRC, and 24 non-IBD/non-CRC controls (11). CRC specimens could not be obtained from IBD-associated CRC patients because these patients typically undergo colectomy upon diagnosis of dysplasia. Although 5 of the 24 (20.8%) non-IBD/non-CRC controls harbored pks+ E. coli, the genotoxic island was detected in 14 of 35 (40%, P < 0.05) IBD patients and in 14 of 21 (66.7%, P < 0.001) CRC patients (Fig. 3B and table S3). This suggests that pks+ bacteria are associated with chronic intestinal inflammation and CRC and may affect carcinogenesis.

Fig. 3

pks+ E. coli strains are associated with CRC and DNA damage. (A and B) PCR screen for pks (A) using primers targeting the left [1824 base pair (bp)] and right (1413 bp) ends of the pks island in E. coli strains NC101 and K12, and E. faecalis (E.f.), and (B) using primers targeting the right end and ClbB gene of the pks island in mucosa-associated E. coli isolated from human colorectal tissue specimens. Binomial test *P < 0.05, ***P < 0.001. (C and D) NC101 pks induces (C) γH2AX (MOI 20, 4 hours) in IEC-6 cells; mean + SEM, analysis of variance (ANOVA) + Tukey, and (D) G2 cell cycle arrest (MOI 100, 24 hours). (A), (C), and (D) are representative of three experiments.

To functionally link pks with the development of CRC, we created an isogenic pks-deficient E. coli NC101 strain (NC101Δpks). Absence of pks did not affect bacterial growth in vitro (fig. S7), nor did it impair colonization capacity in vivo (109 to 1010 per 200 g stool pellet, four to six mice per group). Because pks from strains of extraintestinal pathogenic E. coli can elicit mammalian DNA damage (15, 16), we tested the ability of E. coli NC101 pks to induce a DNA damage response. We infected the nontransformed rat intestinal epithelial cell line IEC-6 with NC101 or NC101Δpks and assessed levels of phosphorylated histone H2AX (γH2AX), which is a surrogate marker of DNA damage (1921). WT NC101 induced γH2AX in ~30% of cells, whereas NC101Δpks induced γH2AX in <5%, which is a level equivalent to that induced by non-colitogenic E. coli K12 (Fig. 3C). Consistent with these results, we observed that WT NC101 induced a threefold increase in the percent of cells arrested in G2/M phase relative to untreated and NC101Δpks-infected cells (Fig. 3D). These experiments demonstrate that pks alone has the capacity to induce DNA damage and indicate that the genotoxic island does not block the initiation of DNA damage response. This led us to hypothesize that pks would also promote tumorigenesis in vivo.

To test this hypothesis, we mono-associated GF Il10−/− mice with E. coli NC101 or NC101Δpks, with or without AOM treatment, and assessed inflammation and tumorigenesis. The absence of pks did not affect the severity of colonic inflammation in Il10−/− mice with colitis (12 weeks with no AOM), or colitis/cancer (14 and 18 weeks with AOM) (Fig. 4A). Similarly, colon tissue pro-inflammatory cytokine transcripts and immune cell infiltration were not significantly different between mice mono-associated with NC101 versus NC101Δpks (figs. S8 and S9 and table S4). However, at both 14 and 18 weeks with AOM, the absence of pks was associated with significantly reduced neoplastic lesions (Fig. 4B). At 14 weeks with AOM, high-grade dysplasia (HGD) or invasive carcinomas were present in five of eight mice mono-associated with NC101, whereas only one of eight NC101Δpks mono-associated mice developed HGD. At 18 weeks with AOM, the absence of pks did not affect mouse survival or tumor size; however, macroscopic tumor burden and carcinoma invasion were significantly decreased (Fig. 4, C to F, and fig. S10). In addition, all nine NC101 mono-associated mice developed invasive carcinoma, with four of nine fully invading the muscularis propria and serosa. In contrast, zero of nine NC101Δpks mono-associated mice exhibited full invasion. This likely suggests that the presence of E. coli pks accelerates progression from dysplasia to invasive carcinoma. In the absence of AOM, GF Il10−/− mice colonized with NC101 for 21 weeks developed only mild dysplasia (fig. S11A). GF WT mice mono-associated with E. coli NC101 and treated with AOM developed neither inflammation nor dysplasia/tumors (fig. S11B), suggesting that this bacterium is not carcinogenic in the absence of inflammation. Together, these data indicate that the absence of pks reduces the tumorigenic potential of E. coli NC101 without altering colonic inflammation.

Fig. 4

Deletion of pks reduces the tumorigenicity, but not inflammatory potential, of E. coli NC101 in AOM/Il10−/− mice. (A) Histologic inflammation and (B) neoplasia scores in three cohorts of mice at 12, 14, and 18 weeks with AOM, and (C to F) 18 weeks with AOM: (C) Histologic invasion score, (D) macroscopic tumor number, (E) mean macroscopic tumor diameter in each mouse, and (F) representative H&E histology. In (A) to (F), each symbol represents data from one mouse, line at mean, pairwise comparisons by t test. (G) Cells/crypt with ≥4 γH2AX foci, and γH2AX IHC (400×). Each symbol represents data from mouse, ANOVA + Tukey, line at mean, and arrowheads indicate γfoci+ cells.

To evaluate the impact of pks on host DNA damage in vivo, we measured colonocyte γH2AX+ nuclear foci (γ-foci) in AOM/Il10−/− mice mono-associated with NC101 versus NC101Δpks for 14 weeks (1921). The abundance of γ-foci+ colonocytes/crypt was significantly reduced in AOM/Il10−/− mice mono-associated with E. coli NC101Δpks versus E. coli NC101 (Fig. 4G). We detected an 80% reduction in γ-foci+ colonocytes/crypt in E. coli NC101 mono-associated AOM/WT mice relative to E. coli NC101-associated AOM/Il10−/− mice (Fig. 4G). This suggests that both host inflammation and E. coli–derived pks act in concert to create a host microenvironment that promotes DNA damage and tumorigenesis in AOM/Il10−/− mice.

Although the etiology of colitis-associated CRC is multifactorial, this work indicates that chronic inflammation targets the intestinal microbiota and can induce the expansion of microbes, including E. coli, that influence CRC in mice. The carcinogenic effect of E. coli NC101 pks clearly demonstrates that genotoxic microorganisms promote CRC in the presence of the carcinogen AOM in Il10−/− mice. It remains to be seen whether NC101 and other pks-harboring bacteria have similar effects in other models of colitis-associated CRC. An increased prevalence of pks+ E. coli in IBD and CRC patients may suggest a cancer-promoting role in human CRC. We propose a model in which inflammation creates an environment that supports carcinogenesis through its effects on both the host and the microbiota. In this two-hit model, inflammation targets the microbiota to foster the expansion of bacteria with genotoxic potential, such as pks+ bacteria. In parallel, inflammation creates an opportunity for pks+ bacteria to adhere to the colonic mucosa by decreasing protective mucins and antimicrobial peptide production (2224)—a process prevented by natural barrier function present in noninflamed WT mice. The genotoxic effect of pks requires bacteria-host cell contact (15, 16); thus, an environment in which bacteria can more readily access the epithelium could result in increased delivery of the pks product Colibactin to epithelial host cells. This would explain the lack of cancer in pks+ E. coli–associated WT mice. Although other microbes likely participate in the progression of CRC, our findings highlight the complex effects of inflammation on both microbial composition/activity and the host’s ability to protect itself from a dysbiotic microbiota (25).

Supplementary Materials

Materials and Methods

Figs. S1 to S11

Tables S1 to S4

References (2639)

References and Notes

  1. Materials and methods are available as supplementary materials on Science Online.
  2. Acknowledgments: We thank M. Bower and S. Tonkonogy of the National Gnotobiotic Rodent Resource Center at University of North Carolina (UNC) and North Carolina State University for assistance with gnotobiotic mice (NIH P40 R018603). Histology was performed at the Center for Gastrointestinal Biology and Diseases histology core (P30 DK034987). This work was supported by funding from NIH T32 DK007737 (J.C.A.), R01 DK73338 (C.J.), R01 DK47700 (C.J.), R01 CA136887 (T.O.K.), R01 DK53347-11 (K.W.S./A.B.S.), the American Institute for Cancer Research (C.J.), UNC University Cancer Research Fund (C.J.), New York Presbyterian/Weill Cornell Medical College (K.W.S.), Crohn’s and Colitis foundation UK (B.J.C.), the NIH Research Specialist Biomedical Research Center in Microbial Disease (J.M.R.), the North West Cancer Research Fund UK (B.J.C.), and the Canadian Institutes of Health Research MOP#114872 (A.S.). T.A. is supported by a scholarship from King Abdulaziz University, through the Saudi Arabian Cultural Bureau in Canada. J.M.R. is a member of advisory boards for Atlantic, Procter and Gamble, and Falk and has received speaking honoraria from Abbott, Falk, Ferring, GlaxoSmithKline, Procter and Gamble, Schering Plough, Shire, and Wyeth. All data presented in this manuscript are tabulated in the main paper and in the supplementary materials. Illumina sequencing data are deposited in National Center for Biotechnology Information’s (NCBI’s) sequence read archive (SRA) and are accessible under SRA055272. Inflammation PCR array data are deposited in NCBI’s Gene Expression Omnibus (GEO) and are accessible through GEO series accession no. GSE39085. This work is in the memory of Mathieu Jobin, Lyne Gauthier, and Janine Drysdale.
View Abstract

Navigate This Article